Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Nimish Maheshwari, an independent analyst and co-founder of Beat The Street, is an investing platform garnering more than 1,00,000+ followers across social media. 
His deep insights and forensic analysis have been featured in some of India's most prominent publications, including the Economic Times, The Morning Context, The Ken,  Dalal Street Investment Journal, Moneylife by Sucheta Dalal, and TheCore.in.
He has a keen eye for identifying red flags in Indian listed companies and has identified exclusive red flags earlier in Adani, Vedanta, Nykaa, Gland Pharma, Brightcom Group etc.

Market & Forensics Analyst

The Take-Rate Reset: How IRDAI's Distribution Draft Repriced Policybazaar and Turtlemint?

Elantas Beck India: Capacity, Localisation And Electrification Open A New Growth Leg

Stylam Industries: Promoter Change, A New Era?

Cyient DLM: The Pivot from Board Assembly to Build-To-Spec Engineering

Inside Adani Airports: $1 Billion Primary Fund Infusion

Wockhardt: Beyond Zaynich,the Franchise Is Just Getting Started

Sterlite Technologies: Project Lakshya Raises The Stakes

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Event-Driven

<ul>
<li>US FDA approved Zaynich (cefepime-zidebactam) on 29–30 May 2026 for adult complicated UTI, days after DCGI clearance on 27 May. An EMA file is already under Accelerated Assessment.</li>
<li>This is the first fully Indian-discovered new chemical entity to win FDA approval. Management points to $1.5–2 billion peak sales against a $7–9 billion resistant Gram-negative opportunity.</li>
<li>Insulin share gains from Novo Nordisk’s disposable-pen exit, Emrok’s India franchise and a 0.10 net-debt-to-equity book give Wockhardt the cash and channels to commercialise without rushed dilution.</li>
</ul>


US FDA approved Zaynich (cefepime-zidebactam) on 29–30 May 2026 for adult complicated UTI, days after DCGI clearance on 27 May. An EMA file is already under Accelerated Assessment.
This is the first fully Indian-discovered new chemical entity to win FDA approval. Management points to $1.5–2 billion peak sales against a $7–9 billion resistant Gram-negative opportunity.
Insulin share gains from Novo Nordisk’s disposable-pen exit, Emrok’s India franchise and a 0.10 net-debt-to-equity book give Wockhardt the cash and channels to commercialise without rushed dilution.


Wockhardt: Zaynich Launch Unlocks a Multi-Market Anti-Infective Franchise

Wockhardt Ltd

Wockhardt: Zaynich Launch Unlocks a Multi-Market Anti-Infective Franchise